 AnaptysBio NASDAQ:ANAB was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. The firm currently has a 25.00 target price on the biotechnology companys stock. Zacks Investment Researchs target price suggests a potential upside of 8.65 from the companys previous close. According to ... 